Stocks and Investing Stocks and Investing
Wed, July 6, 2022
Tue, July 5, 2022

Brian Skorney Maintained (VRTX) at Hold and Held Target at $250 on, Jul 5th, 2022


Published on 2024-10-27 21:45:03 - WOPRAI, Brian Skorney
  Print publication without navigation


Brian Skorney of Baird, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Hold and Held Target at $250 on, Jul 5th, 2022.

Brian has made no other calls on VRTX in the last 4 months.



There are 13 other peers that have a rating on VRTX. Out of the 13 peers that are also analyzing VRTX, 5 agree with Brian's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Brian Abrahams of "RBC Capital" Maintained at Hold and Held Target at $267 on, Sunday, June 12th, 2022
  • David Risinger of "SVB Leerink" Initiated at Hold and Held Target at $265 on, Monday, May 23rd, 2022
  • Do Kim of "Piper Sandler" Maintained at Hold with Decreased Target to $242 on, Friday, May 6th, 2022
  • Paul Matteis of "Stifel" Maintained at Hold with Increased Target to $240 on, Thursday, May 5th, 2022
  • Matthew Harrison of "Morgan Stanley" Upgraded from Sell to Hold and Held Target at $250 on, Tuesday, May 3rd, 2022


These are the ratings of the 8 analyists that currently disagree with Brian


  • Jasper Hellweg of "Argus Research" Maintained at Strong Buy with Increased Target to $280 on, Monday, June 13th, 2022
  • Phil Nadeau of "Cowen & Co." Maintained at Buy with Increased Target to $310 on, Monday, June 13th, 2022
  • Jason McCarthy of "Maxim Group" Upgraded from Hold to Strong Buy and Held Target at $325 on, Wednesday, June 1st, 2022
  • Liisa Bayko of "Evercore ISI Group" Maintained at Buy and Held Target at $278 on, Tuesday, May 24th, 2022
  • Mohit Bansal of "Wells Fargo" Maintained at Buy with Increased Target to $305 on, Friday, May 6th, 2022
  • Gena Wang of "Barclays" Maintained at Buy and Held Target at $291 on, Thursday, May 5th, 2022
  • Colin Bristow of "UBS" Maintained at Strong Buy with Decreased Target to $322 on, Wednesday, April 27th, 2022
  • Hartaj Singh of "Oppenheimer" Maintained at Buy with Increased Target to $350 on, Monday, April 4th, 2022

Contributing Sources